The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Blueprint Medicines Price Target Announced at $100.00/Share by Credit Suisse
Blueprint Medicines analyst ratings
Credit Suisse Initiates Coverage On Blueprint Medicines with Neutral Rating, Announces Price Target of $100
BRIEF-Blueprint Medicines Announces EMA Validation Of Type Ii Variation Marketing Authorization Application For Ayvakyt® (Avapr
Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis
Blueprint Medicines Price Target Raised to $95.00/Share From $90.00 by Barclays
Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $105
Recap: Blueprint Medicines Q4 Earnings
Blueprint Medicines Q4 EPS $(1.53) Beats $(1.62) Estimate, Sales $34.11M Beat $29.24M Estimate
